On October 28, 2011 Topotarget and Multimeric Biotherapeutics reported the signature of an exclusive license agreement granting Multimeric rights to the further development of the multimeric TNF superfamily ligands (TNFSFs) for all therapeutic uses (Press release TopoTarget, OCT 28, 2011, View Source;messageId=580641 [SID:1234500429]). TNFSFs are not a core activity of Topotarget IP assets. Topotarget continue to focus efforts on its lead compound the HDACi belinostat.
Under the agreement, Multimeric will license the rights to all multimeric fusion proteins containing TNFSFs which are covered by Topotarget’s issued and pending patents in Europe, US, Canada, Japan, Australia, South Korea, and other territories. The agreement also grants Multimeric the rights to sub-license.
No details on the terms of the agreement were disclosed

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!